Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 3

1.

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.

Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Canakinumab Study Group, Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T; AIDA Study Group.

Lancet. 2013 Jun 1;381(9881):1905-15. doi: 10.1016/S0140-6736(13)60023-9. Epub 2013 Apr 5.

PMID:
23562090
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Mechanisms underlying the onset of oral lipid-induced skeletal muscle insulin resistance in humans.

Nowotny B, Zahiragic L, Krog D, Nowotny PJ, Herder C, Carstensen M, Yoshimura T, Szendroedi J, Phielix E, Schadewaldt P, Schloot NC, Shulman GI, Roden M.

Diabetes. 2013 Jul;62(7):2240-8. doi: 10.2337/db12-1179. Epub 2013 Mar 1.

PMID:
23454694
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Assessment of substance abusers on the MCMI-III and the Rorschach.

Vanem PC, Krog D, Hartmann E.

Scand J Psychol. 2008 Feb;49(1):83-91. doi: 10.1111/j.1467-9450.2007.00608.x.

PMID:
18190406
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk